Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data

The FDA lifted the clinical hold on Aardvark Therapeutics’ investigational new drug application for ARD-101, which may allow clinical development for PWS-related hyperphagia to resume. Aardvark said it will review data from the terminated Phase 3 HERO trial and the open-label extension trial on an October 23, 2026 webcast; the announcement did not provide trial results.

Analysis

The hold removal clears a regulatory gate, not the central investment question: whether ARD-101 has a reproducible efficacy and safety profile after the terminated Phase 3. The webcast is therefore a high-information, near-term catalyst; the market may initially price the clearance as de-risking while underweighting the possibility that the trial record or FDA conditions leave a costly redesign. Scrutinize the reason for termination, endpoint-level results, missing-data handling, adverse events, and what the FDA requires before enrollment resumes.

Over 1–3 months, a credible protocol and regulator-aligned path could improve AARD’s financing optionality and support a rerating; ambiguous results would leave it exposed to development delay and potential funding dilution. Over 6–18 months, commercial value depends on differentiation against Soleno Therapeutics’ established PWS hyperphagia offering—not merely on restarting development. The key contrarian point: regulatory clearance can be mistaken for clinical validation, especially in a population where caregiver-reported outcomes and trial execution may complicate interpretation. This is a binary, company-specific catalyst; no broad biotech read-through is warranted.

Key Decisions for Investors

• Avoid chasing AARD ahead of the October 23 webcast; treat the event as a data-quality review, not a clinical de-risking milestone.
• After the call, consider a small, risk-defined long only if management provides a coherent explanation for the Phase 3 termination, interpretable efficacy and safety data, and a specific FDA-aligned restart plan. Size for a potential sharp gap against the position.
• Keep AARD on an event watchlist rather than pair-trading it against Soleno Therapeutics until comparative efficacy, tolerability, and commercial differentiation are evidenced.
• Falsify the constructive thesis if the dataset lacks a consistent treatment signal, safety concerns remain unresolved, or FDA conditions require a materially longer or broader trial; verify trial costs and cash runway before underwriting financing optionality.